Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. alleging that the company made false and misleading statements regarding its revenue outlook and growth prospects for Gardasil, particularly in relation to competition and drug approval developments [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Merck created a false impression of having reliable information about its projected revenue and growth for Gardasil while downplaying competitive risks and drug approval challenges [2]. - It is alleged that Merck's optimistic reports regarding growth and demand in China were not reflective of the actual situation, indicating a material decline in the company's ability to drive demand for Gardasil [2]. Group 2: Impact on Stock Price - Following the announcement on July 30, 2024, regarding a significant drop in shipments from its distributor, Merck's stock price fell nearly 10% [3]. - On February 4, 2025, after disclosing a 3% decline in Gardasil sales to $8.6 billion, Merck's stock price dropped more than 9% [4]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of long-term stockholders of Merck and is encouraging individuals with information or questions to reach out [1][5].

Wall Street expects a year-over-year increase in earnings on lower revenues when Merck (MRK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 24. On the othe ...

智通财经4月17日电，蒙特利尔银行将默克公司目标股价从96美元下调至89美元；将辉瑞目标价从36美 元下调至30美元。 ...

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 国家药监局3月批准注册308个医疗器械产品 4月14日消息，国家药监局2025年3月共批准注册医疗器械产品308个。其中，境内第三类医疗器械产品 248个，进口第三类医疗器械产品34个，进口第二类医疗器械产品19个，港澳台医疗器械产品7个。 药械审批 成都赛璟生物熊去氧胆酸口服混悬液获批上市 近日，成都赛璟生物研发的熊去氧胆酸口服混悬液作为国内首仿3.1类新药，正式获批上市。熊去氧胆 酸由德国Dr.Falk Pharma GmbH原研，包含了片剂、胶囊、口服混悬剂等剂型。据介绍，本次获批产品 是国内企业首个且唯一获批治疗罕见病囊性纤维化相关肝病(CFALD)的药物，填补了国内目前上市的熊 去氧胆酸片剂/胶囊剂无此适应证的空白。 21点评：世界卫生组织表明，约80%男人和女人一生中会感染至少一种HPV型别。HPV对外界的抵抗力 相对较强；性行为是感染HPV的主要途径，但不是唯一途径，HPV的感染还可通过母婴传播以及直接接 触传播，如皮肤黏膜接触。长期以来，HPV疫苗主要针对女性，用于预防宫颈癌。这一获批也将提 ...

Company Performance - Merck (MRK) closed at $79.17, reflecting a slight decrease of -0.01% from the previous day, underperforming the S&P 500 which gained 0.79% [1] - The stock has experienced a significant decline of 16.27% over the past month, compared to the Medical sector's loss of 8.97% and the S&P 500's loss of 3.56% [1] Upcoming Earnings - Merck's earnings report is scheduled for April 24, 2025, with an expected EPS of $2.16, representing a 4.35% increase from the same quarter last year [2] - Revenue is anticipated to be $15.48 billion, indicating a decrease of 1.85% compared to the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of $8.96 per share and revenue of $64.99 billion, reflecting increases of +17.12% and +1.27% respectively from the prior year [3] - Recent modifications to analyst estimates are crucial as they often indicate near-term business trends, with positive revisions suggesting a favorable business outlook [3][4] Zacks Rank and Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Merck currently holds a Zacks Rank of 3 (Hold), with a recent 0.53% decline in the Zacks Consensus EPS estimate [5] Valuation Metrics - Merck is trading at a Forward P/E ratio of 8.84, which is lower than the industry average Forward P/E of 13.03 [6] - The company's PEG ratio stands at 0.72, compared to the average PEG ratio of 1.19 for Large Cap Pharmaceuticals [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and currently holds a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [7] - The Zacks Industry Rank evaluates the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2]. - The lawsuit claims that Merck provided misleading information regarding the expected revenue of $11 billion from Gardasil sales by 2030 while concealing adverse facts about demand in China [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has recovered hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 13, 2025 (GLOBE ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided misleading information regarding expected revenue of $11 billion from Gardasil sales by 2030 [4] - Defendants reportedly made overly optimistic statements about Gardasil's demand in China while concealing adverse facts about the actual demand visibility and inflated inventory issues [4]

NEW YORK, April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form ...